Sign in
CompletedNo phase

Validation of SOFA-2 for Mortality and Sepsis-3 Prevalence in Turkey

Key facts

Who runs it
Marmara University
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
3,379 people enrolled
Started
4 May 2026
Ended
10 Aug 2026
Type of study
Observational, 2 groups
Record updated
17 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patients aged 18 years or older
  • Admitted to the Intensive Care Unit (ICU) during the specified study recruitment window
  • For the Validation Cohort: Patients staying in the ICU for at least 24 hours
  • For the Point Prevalence Cohort: Patients present in the ICU at 08:00 AM on the designated "Index Day" or admitted within the subsequent 24 hours

Who cannot take part

  • Patients admitted to Cardiovascular Surgery Intensive Care Units
  • Patients younger than 18 years of age
  • Patients admitted to Pediatric Intensive Care Units
  • Patients admitted to Coronary Care Units (CCU)
  • Patients admitted solely for the purpose of organ donation
  • Patients with missing core data components required for score calculation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational study is to validate the effectiveness of the new SOFA-2 score in predicting mortality and to determine the current frequency of sepsis in adult patients admitted to Intensive Care Units (ICUs) in Turkey. The main questions it aims to answer are:

Read full original descriptionShow less

* Does the SOFA-2 score accurately predict 30-day mortality in ICU patients? * What is the prevalence of Sepsis-3 and septic shock in Turkish ICUs?

Researchers will compare the new SOFA-2 score to the existing SOFA-1 score to see if the new score provides better predictive accuracy for patient outcomes.

Participants will not receive any experimental intervention. Researchers will collect data from routine medical care, including:

* Vital signs, laboratory test results, and details of organ support (such as mechanical ventilation or dialysis) during the first 24 hours of admission. * Survival status at 30 days.

The 2 groups in the trial

  • Primary Validation Cohort

    Adult patients admitted to the ICU during the 7-day prospective recruitment window. Organ dysfunction scores are calculated within the first 24 hours to validate SOFA-2 for 30-day mortality.

  • Point Prevalence Cohort

    All adult patients present in the ICU on the designated single "Index Day" (08:00 to 08:00). Used specifically to determine the point prevalence of Sepsis-3 and septic shock.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Validation of the SOFA-2 Score for 30-Day Mortality in Intensive Care Units in Turkey and Determination of Sepsis-3 Prevalence - A Multicenter Hybrid Observational Study.
Record updated
17 August 2026